[ET Net News Agency, 21 April 2026] Morgan Stanley raised the target price for Giant
Biogene (02367) to HKD43 from HKD42 and maintained the "overweight" rating.
The research house said it is positive for the sales outlook for 2027-28, given GB's
efforts in upgrading the go-to-market operation and expanded product portfolio. (rc)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
32.000 +2.340 (+7.889%) Others
21/04/2026 14:34
{I-bank focus}Morgan raises Giant Biogene (02367) to HKD43
Next︰17/03/2026 10:10 {Block Trade}GIANT BIOGENE: 1.08m shares, or HK$34.51m
17/03/2026 09:37 {Block Trade}GIANT BIOGENE: 645k shares, or HK$20.43m
11/12/2025 16:05 {I-bank focus}UBS lowers Giant Biogene (02367) to HKD39.5
08/12/2025 16:04 {I-bank focus}HSBC lowers Giant Biogene (02367) to HKD46.4
03/12/2025 14:41 {I-bank focus}Citi lowers Giant Biogene (02367) to HKD44.6
02/12/2025 14:00 {Hot Stocks}GIANT BIOGENE quoted at HK$40.42, up 10.5%
| Remark: | Real time quote last updated: 21/04/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |